Simulations Plus, Inc. (SLP)
NASDAQ: SLP · Real-Time Price · USD
14.53
+0.35 (2.47%)
Aug 13, 2025, 4:00 PM - Market closed
Simulations Plus Employees
As of August 31, 2024, Simulations Plus had 247 total employees, including 243 full-time and 4 part-time employees. The number of employees increased by 50 or 25.38% compared to the previous year.
Employees
247
Change (1Y)
50
Growth (1Y)
25.38%
Revenue / Employee
$325,437
Profits / Employee
-$255,846
Market Cap
292.45M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SLP News
- 1 day ago - SIMULATIONS PLUS STOCK: Lose Money on Your Simulations Plus, Inc. (NASDAQ:SLP) Investment? Contact BFA Law about its Securities Investigation - GlobeNewsWire
- 1 day ago - Simulations Plus (SLP) Faces Investor Scrutiny After Asset Impairments and Grant Thornton Contests Company Statements About Dismissal – Hagens Berman - GlobeNewsWire
- 2 days ago - SLP BREAKING INVESTIGATION: BFA Law Announces an Investigation into Simulations Plus, Inc. after Stock Plummets over 25% on Impairment Charges – Contact BFA Law if You Lost Money - GlobeNewsWire
- 2 days ago - SLP BREAKING NEWS: Simulations Plus, Inc. Stock Significantly Declines After Impairment Charge and Auditor Departure -- Investors Urged to Contact BFA Law - Business Wire
- 6 days ago - Simulations Plus (SLP) Faces Investor Scrutiny After Asset Impairments and Grant Thornton Contests Company Statements About Dismissal -- Hagens Berman - GlobeNewsWire
- 13 days ago - SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 16 days ago - Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design - Business Wire
- 4 weeks ago - Simulations Plus: Still Positioned For FDA In‑Silico Trend Despite Near‑Term Headwinds - Seeking Alpha